Delirium

Global Delirium Market to Reach US$41.5 Million by 2030

The global market for Delirium estimated at US$32.7 Million in the year 2024, is expected to reach US$41.5 Million by 2030, growing at a CAGR of 4.0% over the analysis period 2024-2030. Hyperactive Type, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$24.6 Million by the end of the analysis period. Growth in the Hypoactive Type segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.9 Million While China is Forecast to Grow at 7.6% CAGR

The Delirium market in the U.S. is estimated at US$8.9 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$8.5 Million by the year 2030 trailing a CAGR of 7.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Delirium Treatment Market – Key Trends & Drivers Summarized

Why Is Delirium Emerging as a Priority Concern in Acute and Elderly Care?

Delirium, characterized by a sudden onset of confusion, disorientation, and fluctuating levels of consciousness, is increasingly recognized as a serious complication in hospitalized patients—especially among the elderly, ICU patients, and post-operative individuals. Its impact is often underestimated, yet delirium is associated with increased morbidity, prolonged hospital stays, higher healthcare costs, and a greater risk of long-term cognitive decline. As global populations age and the burden of chronic illnesses requiring hospitalization rises, the incidence of delirium is surging across healthcare systems.

Healthcare providers are placing growing emphasis on early identification and prevention of delirium, especially in geriatric wards, surgical recovery units, and intensive care settings. The condition is commonly triggered by multiple risk factors such as infections, polypharmacy, metabolic imbalances, and sudden environmental changes in vulnerable patients. Delirium is no longer viewed as an inevitable part of hospitalization but as a preventable and treatable syndrome, prompting the development of multidisciplinary protocols that combine pharmacological, non-pharmacological, and environmental strategies to manage it effectively.

How Are Diagnostic and Monitoring Tools Evolving to Detect Delirium More Effectively?

Early and accurate detection of delirium remains a critical challenge due to its fluctuating nature and symptom overlap with dementia and depression. This has led to the development and widespread adoption of standardized screening tools such as the Confusion Assessment Method (CAM), the Intensive Care Delirium Screening Checklist (ICDSC), and the 4AT screening tool. These instruments are now integral to clinical protocols, especially in emergency departments, surgical recovery, and geriatric care units. Continuous patient monitoring technologies are also being integrated into ICU settings to track cognitive fluctuations and physiological stress indicators that may signal the onset of delirium.

Digital health innovations are also entering the diagnostic space. AI-powered clinical decision support systems and electronic health record (EHR)-linked alert systems are being deployed to identify high-risk patients based on real-time clinical data. These platforms enable timely interventions such as medication review, environmental modification, hydration support, and sensory reorientation. Mobile apps and bedside assessment tools designed for non-specialist caregivers are also gaining attention, helping improve detection rates in home care and long-term care facilities.

What Therapeutic Strategies Are Gaining Ground in the Management of Delirium?

Management of delirium emphasizes prevention, early intervention, and minimizing underlying triggers. Non-pharmacological interventions remain the gold standard for both prevention and treatment, especially in elderly and post-operative patients. These include orientation strategies, sleep hygiene protocols, noise reduction, pain management, and vision/hearing aids to reduce sensory deprivation. Multicomponent care models such as the Hospital Elder Life Program (HELP) are being adopted by hospitals to systematically address delirium risk factors and improve patient outcomes.

Pharmacological treatments are typically reserved for cases of severe agitation or risk to self and others. Antipsychotics such as haloperidol and atypical agents like quetiapine and olanzapine are sometimes used, although evidence supporting their routine use remains mixed. Research into alternative pharmacotherapies is ongoing, including melatonin and dexmedetomidine for sleep-wake cycle stabilization and neuroprotective agents to minimize cognitive injury. Personalized medicine approaches that account for underlying cognitive status, co-morbidities, and drug sensitivity are becoming increasingly important in delirium care pathways.

What Are the Main Forces Driving the Expansion of the Delirium Management Market?

The growth in the delirium management market is driven by several factors, including the rising global geriatric population, increased hospitalization rates among patients with chronic conditions, and growing awareness among healthcare professionals about the risks and consequences of delirium. As hospitals seek to reduce readmission rates, ICU complications, and long-term cognitive impairment, delirium prevention protocols are being prioritized as part of overall quality care initiatives. National health agencies and accreditation bodies are mandating delirium assessment as part of safety and performance standards.

Technological integration is another growth catalyst, with EHR-based screening tools, AI-enabled clinical decision support, and wearable cognitive monitoring devices streamlining the detection and management process. In parallel, the expansion of multidisciplinary care teams involving geriatricians, neurologists, nurses, and pharmacists is enhancing the standardization of treatment approaches. The push for home-based recovery and remote monitoring post-surgery or ICU stay is also increasing the relevance of community-level delirium care solutions. As healthcare systems become more proactive in addressing neurocognitive complications, the delirium treatment and monitoring landscape is set for significant clinical and commercial expansion

SCOPE OF STUDY:

The report analyzes the Delirium market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Hyperactive Type, Hypoactive Type, Mixed Type); End-Use (Hospitals End-Use, Specialty Care End-Use, Research Centers End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• AbbVie Inc.
• Acadia Pharmaceuticals Inc.
• Akorn Incorporated
• Alkermes plc
• Apotex Inc.
• BioXcel Therapeutics, Inc.
• Ceribell, Inc.
• Delix Therapeutics
• Eleusis Ltd.
• Fresenius Kabi AG
• Glenmark Pharmaceuticals Ltd.
• Johnson & Johnson
• Mind Medicine (MindMed) Inc.
• Mylan N.V.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.